Rapcabtagene Autoleucel — Drug Intelligence | 10 EU Trials

Filter these 10 trials by condition, phase, country and more.

Open in Search →

10 Registered trials

7 Recruiting

3 Completed trials

2 Sponsors

16 Countries

Phase III

Phase II

Phase I/II

Phase I (FiH)

Phase III: 1 Phase II: 3 Phase I/II: 5 Phase I (FiH): 1

Oversight events:

1 serious breach 4 temporary halts 3 corrective measures across 3 trials

View oversight register →

Indications tested

Systemic lupus erythematosus 2 Lupus nephritis 2 Immune-mediated myositis 1 Primary progressive multiple sclerosis 1 Systemic scleroderma 1 Acute lymphocytic leukaemia 1 Chronic lymphocytic leukaemia 1 High-grade B-cell lymphoma 1 Primary mediastinal large B-cell lymphoma 1 B-cell type acute leukaemia 1 Myasthenia gravis 1 Secondary progressive multiple sclerosis 1

Sponsors using this IMP

Novartis Pharma AG 9 Novartis Pharma Services AG 1

All trials

10 total

A study to test the safety and disease progression following YTB323 (rapcabtagene autoleucel) administration in participant with progressive… Recruiting

2024-514006-31-00 Phase I/II 4 countries Novartis Pharma AG
An open-label study to assess the safety, efficacy, and cellular kinetics of YTB323 (rapcabtagene autoleucel) in Relapsingin Relapsing Multi… Recruiting

2024-512714-18-00 Phase I/II 4 countries Novartis Pharma AG
An open-label study to assess safety, efficacy, and cellular kinetics of YTB323 in treatment-resistant generalized myasthenia gravis Recruiting

2024-513589-20-00 Phase I/II 1 country Novartis Pharma AG
A study to assess safety, cellular kinetics and exploratory efficacy of rapcabtagene autoleucel in rheumatoid arthritis and Sjogren’s diseas… Recruiting

2024-514596-18-00 Phase I/II 5 countries Novartis Pharma AG
A clinical trial to learn about the effects of YTB in people with difficult to treat active systemic lupus erythematosus (SLE), or active k… Recruiting

2023-510150-17-00 Phase II 13 countries Novartis Pharma AG
A clinical trial to learn about the effects of YTB323 in people with difficult to treat severe diffuse cutaneous systemic sclerosis (dcSSc) Recruiting

2023-510380-34-00 Phase II 10 countries Novartis Pharma AG
CAR T-cell therapy long term follow-up Recruiting

2023-508128-37-00 Phase III 12 countries Novartis Pharma Services AG
A clinical trial to learn about the effects of YTB323 in people with difficult-to-treat severe inflammatory myopathies (IIM) Ended

2024-514137-38-00 Phase II 5 countries Novartis Pharma AG
An open-label study to assess safety, efficacy and cellular kinetics of YTB323 in severe, refractory systemic lupus erythematosus (srSLE). Ended

2023-510081-27-00 Phase I/II 3 countries Novartis Pharma AG
Study of Rapcabtagene autoleucel (YTB323) in adult patients with CLL/SLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL Ended

2023-507062-34-00 Phase I (FiH) 5 countries Novartis Pharma AG

Showing 1–10 of 10 trials

← All drugs A–Z